Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib and Ruxolitinib in Myelofibrosis with Severe Thrombocytopenia
NCT04543279Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in myelofibrosis (MF), Thrombocytopenia, sponsored by Washington University School of Medicine. Started May 2021; status: terminated.
02
Drugs
fostamatinib
03
Conditions
myelofibrosis (MF)Thrombocytopenia
Beyond the preview
Go deeper on NCT04543279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543279.